Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and markets various products for the unmet needs of patients in the United States. The company is headquartered in Morrisville, North Carolina.
| Revenue (TTM) | $288.06M |
| Gross Profit (TTM) | $264.49M |
| EBITDA | $46.63M |
| Operating Margin | 46.30% |
| Return on Equity | 28.20% |
| Return on Assets | 9.05% |
| Revenue/Share (TTM) | $3.32 |
| Book Value | $1.23 |
| Price-to-Book | 70.62 |
| Price-to-Sales (TTM) | 26.06 |
| EV/Revenue | 26.49 |
| EV/EBITDA | 141.82 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 4159.00% |
| Shares Outstanding | $88.93M |
| Float | $62.34M |
| % Insiders | 12.66% |
| % Institutions | 70.99% |
Volatility is currently expanding
MORRISVILLE, N.C., July 29, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, announced today that it will report its second quarter 2026 financial results on Wednesday, August 12, 2026.
Liquidia, Energy Transfer and PBF Energy offer low-beta exposure as oil-driven volatility rises, backed by growth, stable fees and refining demand.
Liquidia's Yutrepia launch is fueling rapid growth, outperforming United Therapeutics on estimates and share gains despite a higher valuation.
Liquidia's Yutrepia is driving strong growth with rapid commercial adoption as the company expands its pipeline and competes in the evolving PAH market.
LQDA's Yutrepia posts a strong commercial debut, but sustaining growth will hinge on standing out in the crowded PAH market as competition intensifies.
LQDA, FLXS, ELMD and AGX combine low beta, positive price momentum and strong fundamentals to help investors navigate market volatility.
Liquidia has surged 129.7% so far in 2026 as Yutrepia gains traction, driving strong sales, profitability and higher earnings estimates.
Does Liquidia Corporation (LQDA) have what it takes to be a top stock pick for momentum investors? Let's find out.
LQDA's Yutrepia launch is gaining traction, with $130 million in Q1 sales, rising prescriptions and profitability as the company expands in PAH.
LQDA, FLXS and AGX screen as low-beta stocks with positive price moves, solid trading volume and company-specific growth drivers amid market fears.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on LQDA and any ticker you trade — then tracks every position and per-strategy win rate.
